A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
NCT07589686 on ClinicalTrials.gov · last registry update 2026-08-07
An unusually large phase 2: 486 participants, more than double the 114 typical for the stage. Due to report 12 November 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percentage Change in Body Weight between Arms 1 and 6. Sponsors move these dates routinely; any movement since this site started watching is listed below. petrelintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- petrelintide
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Enrollment
- 486
- Started
- 2026-09-30
- Primary completion
- 2027-11-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage Change in Body Weight between Arms 1 and 6
Conditions studied
Obesity or Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the petrelintide page for this molecule’s full trial and approval history.